Alcon, Inc. (ACL) recently entered into an in-licensing agreement with Potentia Pharmaceuticals, a privately-held biotechnology company that focuses on the development of medicines for the treatment of age-related macular degeneration (AMD). Alcon gained the right to develop Potentia's leading drug candidate, POT-4, for the treatment of AMD. Alcon also gained the right to acquire Potentia’s shares on the achievement of certain development milestones and if Alcon opts to continue with the development of POT-4.   Alcon will make upfront payments to Potentia for the initial license and option rights. Potentia is also entitled to receive future payments based on the achievement of several clinical and global regulatory approval milestones for different therapeutic indications and on Alcon's decision to proceed with development. Potentia will also receive royalties based on sales of any products that are approved and commercialized under this agreement.   POT-4 is a complement inhibitor, which is ...

After the closing bell on Wednesday, Solta Medical Inc. (SLTM) announced that the U.S. Food and Drug Administration (FDA) approved its device to clear pigmentation and other superficial skin conditions.   The device, called the Fraxel re:store Dual Laser System, can be used both on the face and large body areas to clear pigmentation through a single treatment.   Solta has already received approval for the device with 1550 nanometer (nm) wavelength for skin resurfacing and treatment of pigmented lesions and certain other dermatological conditions.   The present FDA 510(k) clearance is for the Fraxel 1927 nm laser for dermatological procedures requiring the coagulation of soft tissue. Prior to its approval, laser skin resurfacing procedures were largely limited to the face. The approval of the new 1927 nm wavelength increases the areas of the body that physicians can treat, which are further indications of Solta's continued efforts to ...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Friday September 25, 2009

DrStockPick.com Stock Report!

**************************************************************

Hi-Shear Technology Corporation (NYSE Amex: HSR) today announced that its 2009 Annual Meeting of Stockholders, originally scheduled to be held at 10:00 a.m. on October 30, 2009, has been postponed indefinitely. The postponement was made in connection with the announcement, on September 16, 2009, that Hi-Shear Technology Corporation has entered into a definitive merger agreement with Chemring Group PLC (LSE: CHR), whereby Chemring will acquire Hi-Shear in an all cash transaction for $19.18 per share or approximately $132.0 million.

...

For Immediate Release

Chicago, IL – September 18, 2009 – Zacks Equity Research highlights ON Semiconductor (ONNN) as the Bull of the Day and Developers Diversified (DDR) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Alcon Inc.(ACL), AstraZeneca (AZN) and Allergan, Inc.(AGN).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676

Here is a synopsis of all five stocks:

Bull of the Day:

ON Semiconductor (ONNN) is an OEM of primarily analog semiconductors used within a diverse set of end markets. June quarter results beat consensus expectations, with management guiding for stronger results in the September quarter.

Recent acquisitions, a broad product portfolio, a well diversified business across end markets and geographies, restructuring actions and debt reduction initiatives are other positive factors.

While competition is strong as ever and restrictive covenants and some residual integration

...

Abbott (ABT) yesterday entered into a definitive agreement whereby it will acquire Visiogen, Inc., a privately-held company, for $400 million in cash. Visiogen is focused on the development of innovative products for cataract and refractive patients.

The deal will provide Abbott with access to Visiogen’s next-generation accommodating intraocular lens (IOL) technology, which helps address presbyopia in cataract patients. Visiogen’s first commercial application, Synchrony, is currently available in Europe and under Food and Drug Administration (FDA) review in the U.S.

Synchrony is designed to deliver improved vision at all distances, potentially eliminating the need for glasses or contact lenses, reducing glare and nighttime halos, and improving contrast sensitivity.

This deal is in-line with Abbott’s goal of strengthening its ophthalmic portfolio. As a reminder, Abbott entered the ophthalmology market earlier this year with its acquisition of Advanced Medical Optics. The acquisition of Advanced Medical Optics should help Abbott build its strong medical device business

...

ISTA Pharmaceuticals Inc. (ISTA) yesterday announced that its once-per-day eye drug Xibrom QD displayed successful results in a late-stage study. The multi-center, randomized, double-masked, parallel-group study included 299 subjects who underwent cataract operation in one eye.   ISTA revealed that Xibrom QD eye drops were significantly better than placebo at curing eye inflammation 15 days post cataract surgery. The drug was also successful in eliminating eye pain one day following surgery. No serious adverse events were observed and the safety profile appeared to be consistent with the company’s twice a day Xibrom version, which has already hit the market.   The U.S. marketing rights to Xibrom, which is used for the treatment of ocular inflammation following cataract surgery, were acquired by ISTA in 2002 and the product was launched in the U.S. in 2005. As per IMS data, sales in the first half of 2009 were $33.8 million....

Allergan, Inc. (AGN) once again beat expectations by posting a second-quarter profit of 75 cents per share (up 19% year over year), which was well above the Zacks Consensus Estimate of 68 cents per share. Profits were primarily driven by cost management and efficiencies. However, total revenues declined 3.6% to $1130.8 million in the reported quarter. Specialty pharmaceuticals sales declined 0.6% to $921.2 million. Eyecare pharmaceutical sales declined 2.5%. The strong performance of products like the Alphagan franchise, Lumigan, Combigan and Restasis was offset by weakness in the artificial tears segment. Botox sales declined 3.2% to $336.8 million. In addition to weak consumer spending, we believe negative news surrounding Botox’ safety record have affected sales. Going forward, we expect Botox sales to continue declining especially in the face of additional competition from Medicis Pharma’s (MRX) Dysport, which was launched recently in the U.S. Meanwhile, ...

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

 

Friday July 31, 2009

PennyOmega.com Stock Report!

**************************************************************

FUQI International, Inc. (Nasdaq: FUQI), a leading designer, producer and seller of high quality precious metal jewelry in China, today announced the pricing of an underwritten public offering of common stock. The Company agreed to sell a total of 4,855,000 shares at $21.50 per share (excluding of 726,395 shares that the underwriters may purchase pursuant to a 30-day option to cover over-allotments, if any). All shares are being offered by Fuqi International.

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into

...

ACAD, ACADIA Pharmaceuticals, Inc.

CSRH, Consorteum Holdings Inc, CSRH.OB

DrStockPick Watch List!

DrStockPick Watch List! for Tuesday July 28, 2009

 

My Picks for Tuesday July 28, 2009 are:

**************************************************************

ACAD, ACADIA Pharmaceuticals, Inc.

ACAD is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders.

ACAD focuses on developing a portfolio of its four advanced product candidates, including Pimavanserin, which is in phase III development for Parkinson’s disease psychosis; and a product candidate in phase II for chronic pain and a product candidate in phase I for glaucoma, each in collaboration with Allergan,

...

UBS U.S. Large Cap Growth A (BNLGX) was incepted in December 1998. The investment seeks long-term capital appreciation.

The fund invests in the stocks of large companies with market-capitalization values generally of at least $6 billion at the time of purchase. In addition, it may invest up to 20% of its assets in foreign securities. The fund is non-diversified.

Allergan Inc. (AGN - Analyst Report), Visa Inc. (V - Snapshot Report) and Qualcomm Inc. (QCOM - Analyst Report) are among the top holdings at the fund.

UBS

...